A calculator to predict benefit from adjuvant transarterial chemoembolization for hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the most commonly diagnosed cancer of the liver and the fourth leading cause of cancer-related mortality worldwide, with China accounting for over half of the global annual cases and deaths. Hepatectomy is the standard curative-intent treatment option for appropriately selected patients with localized HCC.

Leave A Comment

Your email address will not be published. Required fields are marked *